Cambridge biotech will invest $250M in Mass. production facility, add jobs [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
The expansion will add an as-yet-unspecified number of jobs, said Timothy Maines, Alnylam's chief technical operations and quality officer, and enable the company to produce drugs at much higher volumes than it can today. Alnylam has drugs on the market today that treat rare kidney, heart and liver disorders, along with a hemophilia drug that was approved by the Food and Drug Administration earlier this year. But the company is developing drugs for conditions that affect larger populations — such as high blood pressure, fatty liver disease, diabetes and obesity. The plant expansion will allow Alnylam to make more of those medicines as they move from the testing phase into the market, Maines said. The company is a pioneer of an approach called “RNA interference,” which uses strands of RNA — ribonucleic acid — to block the biological mechanisms that cause certain diseases. Maines says that the plant expansion will allow it to make these RNA interference medicines using a new, fas
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues [Yahoo! Finance]Yahoo! Finance
- Alnylam plans $250m investment in Norton manufacturing facility, US [Yahoo! Finance]Yahoo! Finance
- Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics [Yahoo! Finance]Yahoo! Finance
- Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi TherapeuticsBusiness Wire
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Leerink Partners from $370.00 to $351.00. They now have a "market perform" rating on the stock.MarketBeat
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 12/11/25 - Form 8-K
- 12/3/25 - Form 8-K
- 12/1/25 - Form 4
- ALNY's page on the SEC website